Deleting Endocannabinoid Enzymes Reshapes Lipid Signaling Across Eight Brain Regions
Deleting the enzymes that break down endocannabinoids had wide-ranging effects on lipid signaling throughout the brain, extending far beyond just endocannabinoids to affect prostaglandins, arachidonic acid, and dozens of related lipids.
Quick Facts
What This Study Found
The endocannabinoid system is often thought of in terms of two molecules (anandamide and 2-AG) and two receptors (CB1 and CB2). This study revealed it is far more interconnected with broader lipid signaling networks than previously appreciated.
Using mice with deleted FAAH, MAGL, or CB1 receptors, researchers measured over 70 lipids across eight brain regions. The findings were striking:
Deleting MAGL (which breaks down 2-AG) massively increased 2-AG levels while significantly reducing arachidonic acid and the inflammatory prostaglandin PGE2 throughout the brain. Deleting FAAH (which breaks down anandamide) increased anandamide but did not affect arachidonic acid or PGE2, suggesting FAAH-derived arachidonic acid does not contribute to steady-state inflammatory lipid levels.
Deleting CB1 receptors left anandamide and 2-AG unchanged but increased PGE2 in most brain areas, suggesting the receptor itself normally limits inflammatory signaling.
Key Numbers
Over 70 lipids measured per sample. 8 brain regions analyzed. MAGL deletion: 2-AG up, AA and PGE2 down throughout brain. FAAH deletion: AEA up, no change in AA or PGE2. CB1 deletion: AEA and 2-AG unchanged, PGE2 up in most regions.
How They Did This
Targeted lipidomics in FAAH knockout, MAGL knockout, and CB1 knockout mice compared to wild-type controls. Over 70 lipids measured per sample using HPLC/MS/MS across eight brain regions (brainstem, cerebellum, cortex, hippocampus, hypothalamus, midbrain, striatum, thalamus).
Why This Research Matters
This study fundamentally expands our understanding of what the endocannabinoid system does. Rather than being an isolated signaling system, it is deeply embedded in broader lipid networks that control inflammation, neurotransmission, and cell function. This has major implications for predicting the effects of drugs that target endocannabinoid enzymes.
The Bigger Picture
Drugs that inhibit FAAH or MAGL are being developed for pain, anxiety, and other conditions. This study shows that these drugs will affect far more than just endocannabinoid levels, with potentially beneficial (anti-inflammatory for MAGL inhibitors) or unpredicted (off-target lipid changes) consequences.
What This Study Doesn't Tell Us
Knockout models represent complete gene deletion, which is more extreme than pharmacological inhibition. Steady-state lipid levels may not reflect dynamic changes during actual signaling. Mouse brain lipid metabolism may differ from humans. Regional variation was observed but not always explained.
Questions This Raises
- ?Do MAGL inhibitors' anti-inflammatory effects (via reduced PGE2) contribute to their therapeutic potential?
- ?Why does FAAH-derived arachidonic acid not contribute to steady-state prostaglandin levels?
- ?Could the off-target lipid effects explain unexpected side effects of endocannabinoid-modulating drugs?
Trust & Context
- Key Stat:
- MAGL deletion reduced inflammatory PGE2 throughout the brain alongside 2-AG increases
- Evidence Grade:
- Comprehensive lipidomics study with multiple knockout models and eight brain regions, but entirely in mice with uncertain clinical translation.
- Study Age:
- Published in 2016. Understanding of the endocannabinoid lipidome has continued to expand with improved analytical methods.
- Original Title:
- Broad impact of deleting endogenous cannabinoid hydrolyzing enzymes and the CB1 cannabinoid receptor on the endogenous cannabinoid-related lipidome in eight regions of the mouse brain.
- Published In:
- Pharmacological research, 110, 159-172 (2016)
- Authors:
- Leishman, Emma(2), Cornett, Ben, Spork, Karl, Straiker, Alex, Mackie, Ken, Bradshaw, Heather B
- Database ID:
- RTHC-01206
Evidence Hierarchy
Tests effects in animals (usually mice or rats), not humans.
What do these levels mean? →Frequently Asked Questions
What happens when you block the enzymes that break down endocannabinoids?
It's not just endocannabinoid levels that change. Blocking MAGL (which breaks down 2-AG) also reduces inflammatory prostaglandins throughout the brain, while blocking FAAH (which breaks down anandamide) increases anandamide without affecting inflammation.
Why does this matter for drug development?
Drugs targeting endocannabinoid enzymes are being developed for pain and anxiety. This study shows these drugs will have effects far beyond endocannabinoids, affecting inflammatory signaling and dozens of other lipids in the brain.
Read More on RethinkTHC
- THC-amygdala-anxiety-brain
- anandamide-weed-withdrawal
- cannabinoid-receptors-recovery-time
- cannabis-developing-brain-teenagers
- cant-enjoy-anything-without-weed
- dopamine-recovery-after-quitting-weed
- endocannabinoid-system-explained-simply
- endocannabinoid-system-withdrawal
- nervous-system-weed-withdrawal-fight-flight
- teen-weed-use-under-18-effects-brain
- thc-brain-withdrawal
- thc-prefrontal-cortex-brain-effects
- weed-cortisol-stress-hormones
- weed-memory-loss-recovery
- weed-motivation-amotivational-syndrome
- weed-nervous-system-effects
- weed-reward-system-brain
Cite This Study
https://rethinkthc.com/research/RTHC-01206APA
Leishman, Emma; Cornett, Ben; Spork, Karl; Straiker, Alex; Mackie, Ken; Bradshaw, Heather B. (2016). Broad impact of deleting endogenous cannabinoid hydrolyzing enzymes and the CB1 cannabinoid receptor on the endogenous cannabinoid-related lipidome in eight regions of the mouse brain.. Pharmacological research, 110, 159-172. https://doi.org/10.1016/j.phrs.2016.04.020
MLA
Leishman, Emma, et al. "Broad impact of deleting endogenous cannabinoid hydrolyzing enzymes and the CB1 cannabinoid receptor on the endogenous cannabinoid-related lipidome in eight regions of the mouse brain.." Pharmacological research, 2016. https://doi.org/10.1016/j.phrs.2016.04.020
RethinkTHC
RethinkTHC Research Database. "Broad impact of deleting endogenous cannabinoid hydrolyzing ..." RTHC-01206. Retrieved from https://rethinkthc.com/research/leishman-2016-broad-impact-of-deleting
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.